Global Leading Market Research Publisher QYResearch announces the release of its latest report “Drugs to Treat Chronic Kidney Disease – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. This report provides a comprehensive analysis of the global drugs to treat chronic kidney disease market, directly addressing the critical therapeutic challenges facing nephrologists and CKD patients: managing mineral and bone disorders (CKD-MBD) including secondary hyperparathyroidism (SHPT), hyperphosphatemia, and hyperkalemia; slowing disease progression through renin-angiotensin-aldosterone system (RAAS) blockade and novel SGLT2 inhibitors; and coordinating complex polypharmacy regimens across multiple drug classes. For pharmaceutical executives, healthcare investors, and formulary managers, understanding market share distribution across drug classes (calcimimetics, vitamin D sterols, phosphate binders, potassium binders), the impact of recent label expansions (SGLT2 inhibitors for CKD regardless of diabetes status), and regional CKD prevalence trends is essential for strategic portfolio planning and market access decisions.
Chronic kidney disease (CKD) affects approximately 850 million people globally (10-12% of the adult population), with prevalence rising due to aging populations, diabetes (30-40% of diabetics develop CKD), and hypertension. Late-stage CKD (Stage 4-5, eGFR <30 mL/min/1.73m²) requires management of multiple metabolic complications: secondary hyperparathyroidism (SHPT) due to declining vitamin D activation and rising fibroblast growth factor-23 (FGF23); hyperphosphatemia (phosphate retention contributes to vascular calcification and cardiovascular mortality); hyperkalemia (potassium retention leading to cardiac arrhythmias); and anemia (erythropoietin deficiency). Key drug classes include: calcimimetics (cinacalcet, etelcalcetide) that increase calcium-sensing receptor sensitivity, suppressing PTH; vitamin D sterols (calcitriol, paricalcitol, doxercalciferol) that suppress PTH; phosphate binders (calcium acetate, sevelamer, lanthanum carbonate, ferric citrate, sucroferric oxyhydroxide) that reduce dietary phosphate absorption; potassium binders (patiromer, sodium zirconium cyclosilicate) that reduce serum potassium; and RAAS inhibitors (ACE inhibitors, ARBs) and SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) that slow CKD progression.
According to QYResearch’s proprietary data, the global drugs to treat chronic kidney disease market was valued at approximately US28.5billionin2025andisprojectedtoreachUS28.5billionin2025andisprojectedtoreachUS 45.2 billion by 2032, growing at a CAGR of 6.8% during the forecast period 2026-2032. CKD-MBD-specific drugs (calcimimetics, vitamin D sterols, phosphate binders, potassium binders) represent approximately 25-30% of this market (US$ 7-8.5 billion in 2025), with RAAS inhibitors (primarily generic, lower value) and SGLT2 inhibitors (high-value, rapidly growing) comprising the remainder. North America holds the largest market share (approximately 40%), driven by high CKD prevalence (37 million US adults), favorable reimbursement (Medicare covers dialysis patients, Part D covers oral CKD drugs), and high adoption of novel binders and SGLT2 inhibitors. Europe follows (28%), Asia-Pacific (18-20%) is the fastest-growing region (projected 9.5% CAGR), driven by rising CKD prevalence in China (estimated 120-150 million CKD patients) and India, as well as expanding treatment access.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5972575/drugs-to-treat-chronic-kidney-disease
1. Product Type Segmentation: Drug Classes for CKD-MBD Management
The market research landscape for drugs to treat chronic kidney disease (focused on CKD-MBD therapies) is defined by mechanism of action and clinical indication. Five primary drug categories dominate the CKD-MBD segment:
- Phosphate Binders (35-40% of CKD-MBD drug revenue): The largest segment, reducing dietary phosphate absorption in Stage 4-5 CKD and dialysis patients (target serum phosphate 2.5-4.5 mg/dL). Sub-categories include:
- Calcium-based binders (calcium acetate, calcium carbonate): Lowest cost (US$ 0.10-0.50 per gram of elemental calcium), but concerns about calcium loading and vascular calcification have reduced market share from 60% (2010) to 30-35% (2025).
- Sevelamer (RenaGel, Renvela) : Non-calcium, non-metal polymer binder; market leader in US/EU with US$ 1.2-1.5 billion annual sales (generic since 2020, but branded Renvela still significant). Reduces LDL cholesterol as secondary benefit.
- Lanthanum carbonate (Fosrenol) : Non-calcium, metal-based (lanthanum) binder; concerns about bone deposition (theoretical, not clinically demonstrated) limit share.
- Iron-based binders (ferric citrate (Auryxia), sucroferric oxyhydroxide (Velphoro)): Dual benefit—phosphate binding + iron repletion (reduces IV iron and ESA requirements). Fastest-growing segment (12% CAGR).
A representative case: A post-hoc analysis of the CREDENCE trial (published January 2026, 4,400 patients with T2D and CKD) demonstrated that SGLT2 inhibitor (canagliflozin) reduced serum phosphate by 0.3-0.5 mg/dL independent of binders, potentially reducing binder dose requirements for some patients, though guidelines still recommend binders for hyperphosphatemia.
- Calcimimetics (20-25%): Cinacalcet (Sensipar/Mimpara) and intravenous etelcalcetide (Parsabiv) for SHPT in dialysis patients (PTH targets 150-300 pg/mL). Cinacalcet generic since 2018 has reduced prices (US1−2perpillgenericvs.US1−2perpillgenericvs.US 10-15 branded), but etelcalcetide (patent protection until 2028) captures higher value (US$ 200-400 per IV dose). Calcimimetics reduce PTH without increasing calcium/phosphate, differentiating from vitamin D sterols.
- Vitamin D Sterols (15-20%): Active vitamin D analogs (calcitriol, paricalcitol, doxercalciferol) suppress PTH by activating intestinal vitamin D receptor (increasing calcium absorption) and directly suppressing parathyroid gland. Paricalcitol (Zemplar) has less hypercalcemic effect than calcitriol, preferred in US/EU. Generic availability (since 2015-2020) has reduced prices significantly (US$ 0.50-2 per capsule).
- Potassium Binders (8-12%): Patiromer (Veltassa, US300−600permonth)andsodiumzirconiumcyclosilicate(Lokelma,US300−600permonth)andsodiumzirconiumcyclosilicate(Lokelma,US 400-800 per month) for hyperkalemia in CKD patients on RAAS inhibitors. This is the fastest-growing segment (15% CAGR) driven by guideline recommendations to continue RAAS inhibition (which improves CKD outcomes) despite hyperkalemia, using binders to manage potassium.
- Other (5-8%): Anemia treatments (erythropoiesis-stimulating agents – ESAs, IV iron, HIF-PH inhibitors like roxadustat), CKD progression agents (SGLT2 inhibitors, RAAS inhibitors – largely generic, lower $ value but high volume).
2. Application Segmentation: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
- Retail Pharmacies (45-50% of 2025 revenue): The largest distribution channel for oral CKD-MBD drugs (phosphate binders, calcimimetics, vitamin D sterols, potassium binders) for non-dialysis CKD patients (Stage 3b-5) and dialysis patients who fill prescriptions at community pharmacies. Chain pharmacies (CVS, Walgreens, Boots) dominate. Reimbursement varies: Medicare Part D (US) covers oral CKD drugs; similar coverage in EU/Japan. Price sensitivity moderate; generic penetration high for older products.
- Hospital Pharmacies (30-35%): Primarily for IV drugs (etelcalcetide for SHPT, IV iron, IV ESA) administered in dialysis centers or hospital infusion suites. Also for inpatient CKD management (acute kidney injury, CKD exacerbations, post-transplant care). Hospital pharmacies benefit from bulk purchasing (GPO pricing) but face formulary constraints.
- Online Pharmacies (15-20%): Growing channel (25% CAGR) for maintenance CKD medications, particularly for stable patients with refill prescriptions. Patient convenience (home delivery), auto-refill programs, and lower prices (discount cards, international pharmacies) drive adoption. Regulatory scrutiny (legitimate vs. counterfeit online pharmacies) remains a concern.
3. Competitive Landscape: Global Market Share Analysis
The drugs to treat chronic kidney disease market includes large pharmaceutical companies with diversified portfolios. Key players and estimated market share positions in the CKD-MBD segment:
- Amgen Inc. (USA): Holds approximately 12-15% market share in CKD-MBD, with Sensipar/Mimpara (cinacalcet) and Parsabiv (etelcalcetide) leading calcimimetics category. Sensipar generic erosion ongoing, but Parsabiv patent extends to 2028-2029.
- Fresenius Medical Care (Germany) and Sanofi: Co-promote Velphoro (sucroferric oxyhydroxide), a leading iron-based phosphate binder with dual benefits. Approximate combined share 8-10% in phosphate binder segment.
- Vifor Pharma (Switzerland, part of CSL Vifor): Commands approximately 6-8% market share, with Veltassa (patiromer, potassium binder) and iron-based binders.
- AstraZeneca (UK/Sweden): Holds approximately 5-7% market share in CKD-MBD through Lokelma (sodium zirconium cyclosilicate, potassium binder) and CKD progression agents (dapagliflozin – Farxiga, approved for CKD 2021, SGLT2 inhibitor). Lokelma growing rapidly (25% CAGR).
- AbbVie Inc. (USA): Accounts for approximately 4-6% market share, with Zemplar (paricalcitol) leading vitamin D sterol segment.
- Bayer AG (Germany): Holds approximately 3-5% market share, with calcium acetate (PhosLo) and other binders.
- Sanofi SA (France): Commands approximately 3-5% market share, with Renagel/Renvela (sevelamer) co-promoted.
Other notable players include Pfizer, Johnson & Johnson, Novartis, Bristol-Myers Squibb, Eli Lilly (Jardiance – empagliflozin, SGLT2 inhibitor for CKD), Boehringer Ingelheim (Jardiance co-promote), Novo Nordisk (Ozempic/Wegovy – GLP-1 receptor agonist with CKD benefits), Teva (generic calcimimetics, binders), Otsuka, Takeda, and numerous generic manufacturers.
4. Unique Industry Observation: SGLT2 Inhibitors Reshaping CKD Landscape
A distinctive industry dynamic rarely highlighted in standard market reports is the transformative impact of SGLT2 inhibitors on the CKD treatment paradigm—expanding beyond their original diabetes indication into CKD management and creating new market dynamics.
Pre-SGLT2 era (pre-2020) : CKD treatment focused on blood pressure control (RAAS inhibition) and managing metabolic complications (binders, calcimimetics, vitamin D, ESA/iron). Disease progression was inevitable for many Stage 3-4 patients reaching dialysis within 5-10 years.
Post-SGLT2 era (2020-present) : Large cardiovascular outcome trials (CREDENCE, DAPA-CKD, EMPA-KIDNEY) demonstrated that SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) reduce CKD progression by 30-40% (relative risk reduction for end-stage kidney disease), regardless of diabetes status. Regulatory approvals expanded (FDA approved dapagliflozin for CKD, 2021; empagliflozin for CKD, 2022). SGLT2 inhibitors are now recommended in KDIGO guidelines as first-line therapy (with RAAS inhibitors) for CKD patients with albuminuria, eGFR >20-25 mL/min/1.73m².
Market impact: SGLT2 inhibitors (Farxiga US500−600permonth,JardianceUS500−600permonth,JardianceUS 500-550) add US$ 5-7 billion annually to CKD drug market, with growth projected at 10-12% CAGR through 2032. For CKD-MBD drug companies (binders, calcimimetics, vitamin D), the impact is mixed: SGLT2 inhibitors slow disease progression, potentially delaying need for binders/calcimimetics (fewer patients reach Stage 4-5), but patients reaching later stages still require these therapies. The net effect is likely small (1-2% reduction in CKD-MBD drug demand growth rate).
5. Market Outlook and Strategic Recommendations for 2026-2032
By 2032, the global drugs to treat chronic kidney disease market size is expected to reach US45.2billion(US45.2billion(US 14-16 billion for CKD-MBD segment), growing at a 6.8% CAGR. Phosphate binders will remain the largest CKD-MBD segment, with iron-based binders growing fastest (12% CAGR). However, three challenges and opportunities shape the outlook:
- Generic erosion: Cinacalcet (calcimimetics), sevelamer (binders), and paricalcitol (vitamin D) are generic, compressing margins. Novel binders (ferric citrate, sucroferric oxyhydroxide) and new calcimimetics (etelcalcetide) maintain higher pricing through patent protection.
- SGLT2 inhibitor expansion: Farxiga, Jardiance, and upcoming generics (canagliflozin generic expected 2027-2028) may reduce CKD progression rates, modestly reducing demand for late-stage CKD-MBD drugs.
- Cardiovascular outcome trial evidence: Positive results for potassium binders (patiromer, Lokelma) on cardiovascular outcomes (ongoing DIAMOND trial expected 2026-2027) could expand utilization beyond hyperkalemia management to routine use with RAAS inhibitors.
For hospital formulary managers and pharmaceutical investors, this market research suggests:
- Iron-based phosphate binders (Auryxia, Velphoro) offer best value proposition: phosphate control + iron repletion (reduces ESA and IV iron costs)
- SGLT2 inhibitors (Farxiga, Jardiance) should be standard of care for CKD patients with albuminuria, regardless of diabetes status
- Potassium binders (Veltassa, Lokelma) are essential for RAAS inhibitor optimization in hyperkalemic patients; monitor DIAMOND trial results for cardiovascular indication expansion
The complete report, including Full TOC, 38 data tables, 32 figures, and detailed drug class analysis, is available via the sample PDF link above.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
